Lazard Asset Management’s Coherus Oncology CHRS Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$17.8K	Buy	+10,514	New	+$18.7K	﹤0.01%	1810
2024 Q4	–	Sell	-883,729	Closed	-$919K	–	2312
2024 Q3	$919K	Buy	883,729 +252,982	+40%	+$347K	﹤0.01%	1108
2024 Q2	$1.09M	Buy	630,747 +243,047	+63%	+$489K	﹤0.01%	959
2024 Q1	$926K	Buy	387,700 +374,307	+2,795%	+$921K	﹤0.01%	937
2023 Q4	$44K	Sell	13,393 -443,192	-97%	-$1.19M	﹤0.01%	1914
2023 Q3	$1.71M	Sell	456,585 -93,938	-17%	-$434K	﹤0.01%	893
2023 Q2	$2.35M	Buy	550,523 +173,190	+46%	+$1.02M	﹤0.01%	861
2023 Q1	$2.58M	Buy	377,333 +59,611	+19%	+$463K	﹤0.01%	869
2022 Q4	$2.52M	Buy	317,722 +156,746	+97%	+$1.21M	﹤0.01%	872
2022 Q3	$1.55M	Buy	160,976 +152,754	+1,858%	+$1.55M	﹤0.01%	932
2022 Q2	$59K	Sell	8,222 -14,666	-64%	-$128K	﹤0.01%	1736
2022 Q1	$295K	Sell	22,888 -23,486	-51%	-$299K	﹤0.01%	1194
2021 Q4	$740K	Buy	46,374 +38,531	+491%	+$674K	﹤0.01%	1047
2021 Q3	$126K	Sell	7,843 -14,374	-65%	-$211K	﹤0.01%	1363
2021 Q2	$307K	Sell	22,217 -62,859	-74%	-$890K	﹤0.01%	1152
2021 Q1	$1.24M	Buy	85,076 +25,179	+42%	+$427K	﹤0.01%	870
2020 Q4	$1.04M	Buy	+59,897	New	+$1.07M	﹤0.01%	887
2017 Q3	–	Sell	-49,100	Closed	-$704K	–	989
2017 Q2	$704K	Buy	+49,100	New	+$944K	﹤0.01%	682